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ttp://dx.doi.org/10.1016/j.ajpath.2015.02.004Drug-induced gingival overgrowth is caused by the antiseizure medication phenytoin, calcium channel
blockers, and ciclosporin. Characteristics of these drug-induced gingival overgrowth lesions differ. We
evaluate the ability of a mouse model to mimic human phenytoin-induced gingival overgrowth and
assess the ability of a drug to prevent its development. Lovastatin was chosen based on previous
analyses of tissue-speciﬁc regulation of CCN2 production in human gingival ﬁbroblasts and the known
roles of CCN2 in promoting ﬁbrosis and epithelial to mesenchymal transition. Data indicate that anterior
gingival tissue overgrowth occurred in phenytoin-treated mice based on gross tissue observations and
histomorphometry of tissue sections. Molecular markers of epithelial plasticity and ﬁbrosis were regu-
lated by phenytoin in gingival epithelial tissues and in connective tissues similar to that seen in humans.
Lovastatin attenuated epithelial gingival tissue growth in phenytoin-treated mice and altered the ex-
pressions of markers for epithelial to mesenchymal transition. Data indicate that phenytoin-induced
gingival overgrowth in mice mimics molecular aspects of human gingival overgrowth and that lovastatin
normalizes the tissue morphology and the expression of the molecular markers studied. Data are
consistent with characterization of phenytoin-induced human gingival overgrowth in vivo and in vitro
characteristics of cultured human gingival epithelial and connective tissue cells. Findings suggest that
statins may serve to prevent or attenuate phenytoin-induced human gingival overgrowth, although
speciﬁc human studies are required. (Am J Pathol 2015, 185: 1588e1599; http://dx.doi.org/10.1016/
j.ajpath.2015.02.004)Supported by NIH/National Institute of Dental and Craniofacial Research
grant R01DE011004 (P.C.T.) and by a scholarship from the Faculty of
Dentistry, King Abdulaziz University, Ministry of Higher Education, Saudi
Arabia (M.A.A.).
Disclosures: None declared.Gingival overgrowth is principally a tissue-speciﬁc adverse
effect of the antiseizure drug phenytoin, antihypertensive
calcium channel blockers, and the immunosuppressant ciclo-
sporin (formerly cyclosporine A). Oral complications of
gingival overgrowth include difﬁculty inmaintaining adequate
oral hygiene that can have systemic consequences related to
excess inﬂammation. More than 3 million Americans have
seizure disorders, 20% of whom continued to receive
phenytoin principally because of grand mal epilepsy. Alter-
nativemedications can sometimes be prescribed, but this is not
possible for patients with grand mal epileptic seizures, which
are optimally treated with phenytoin. Some patients require the
calcium channel blocker nifedipine to treat hypertension and
cannot tolerate other antihypertensive drugs.1 Similarly,
although tacrolimus is now often substituted for cyclosporin,
data indicate that gingival overgrowth still occurs, albeit with
delayed onset and perhaps reduced severity.1,2 The currentstigative Pathology.
.surgical therapy for drug-induced gingival overgrowth is
gingivectomy. Gingivectomy is unsatisfactory because in
many cases there is a need for repeated operations due to
recurrence of the disease. In addition, the surgical approach
leads to substantial patient discomfort and risk of infection.
There remains, therefore, a need to investigate tissue-speciﬁc
mechanisms and develop therapeutic approaches to treat this
disﬁguring and detrimental craniofacial disease.
Analyses of tissue-speciﬁc characteristics of human
gingival overgrowth clinical samples and in vitro pathway
analyses using primary human gingival ﬁbroblasts and
Statins and Phenytoin Gingival Overgrowthepithelial cells have resulted in identiﬁcation of speciﬁc
pathological processes and pharmacological approaches to
potentially prevent or alleviate gingival overgrowth.3e5
These studies have focused on pathways that regulate
CCN2, also known as connective tissue growth factor,
which is highly elevated in phenytoin-induced gingival
overgrowth and in idiopathic human gingival ﬁbromatosis,
which are both ﬁbrotic, unlike some other forms of gingival
overgrowth, which are not ﬁbrotic.6 CDC42 and RAC1 are
small G-proteins that require lipid modiﬁcation for activity
and are critical mediators of transforming growth factor
(TGF)-b1einduced CCN2 expression in a tissue-speciﬁc
manner.4 Lipid modiﬁcations of CDC42 and RAC1 are
required for activation and are derived from the cholesterol
biosynthetic pathway.7 Inhibition of the cholesterol
biosynthetic pathway by the HMG-CoA reductase inhibitors
lovastatin and simvastatin inhibits TGF-b1einduced CCN2
expression in primary human gingival ﬁbroblasts.4 Lova-
statin is an approved drug in widespread use for the treat-
ment of hypercholesteremia. Therefore, we wished to
determine whether in vivo administration of lovastatin could
prevent the development of gingival overgrowth in a
mouse model. We report both the development of a mouse
model of phenytoin-induced gingival overgrowth in mice
and its use to determine the effectiveness of lovastatin to
prevent the development of gingival overgrowth and to
normalize the expression of Ccn2 and other proteins
associated with phenytoin-induced gingival overgrowth.
Data are consistent with earlier in vitro studies that iden-
tiﬁed molecular pathways that drive phenytoin-induced
gingival overgrowth in humans in a tissue-speciﬁc
manner.3,4Materials and Methods
Phenytoin was purchased from Henry Schein Corporation
(NDC 0641-0493; Roswell, GA). Lovastatin was purchased
from EMDMillipore (Calbiochem, 438186; Billerica, MA).
Physiological sterile saline was purchased from the Labo-
ratory Animal Science Center at Boston University. Pro-
pylene glycol was purchased from MP Biomedical,
(151957; Santa Ana, CA). Harris modiﬁed hematoxylin
(SH-30), eosin B (E514), and eosin Y (E511) were pur-
chased from Fisher Scientiﬁc (Hampton, NH). Rabbit
polyclonal anti-Tgfb1 IgG and blocking peptide were pur-
chased from Santa Cruz Biotechnology (sc-146; Dallas,
TX). Rabbit polyclonal anti-CTGF/CCN2 (ab6992) anti-
body was purchased from Abcam (Cambridge, MA). Rabbit
polyclonal anti LOXL2 IgG (105085) was purchased from
GeneTex (Irvine, CA) and mouse LOXL2 shRNA plasmids
were purchased from Sigma (St Louis, MO). Mouse
monoclonal anti E-cadherin IgG was purchased from BD
Bioscience (610181; San Jose, CA). Immunoperoxidase
detection kits and reagents were purchased from Vector
Laboratories (Burlingame, CA).The American Journal of Pathology - ajp.amjpathol.orgHuman Gingival Samples
Human gingival samples were collected from patients
with severe gingival overgrowth who were treated with
phenytoin for epilepsy and subjected to gingivectomy
and from systemically healthy individuals undergoing
crown-lengthening surgery. Samples were collected at the
Department of Periodontology and Oral Biology and the
Clinical Research Center of Boston University at the
Goldman School of Dental Medicine and the Franciscan
Children’s Hospital and Rehabilitation Center. Informed
consent forms were signed by all donors. The consent forms
and study protocols were approved by the Institutional
Review Board of Boston University Medical Center. All
excised tissues were ﬁxed in 4% paraformaldehyde in
phosphate-buffered saline at 4C for 4 hours and then
incubated in cold 30% sucrose overnight. Tissues were then
stored in 2-methylbutane at 80C. At least twenty 5-mm
serial sections per sample were made on a cryostat and were
stored at 80C.
Mouse Model
Eight-week-old BALB/cByJ male mice were purchased
from Jackson Laboratory (Cat# 001026; Bar Harbor, ME).
Mice were housed for 1 week before any procedure for
acclimation. Mice were then divided into groups.
Control groups consisted of a negative control group
receiving physiological saline (NaCl 0.9%, n Z 8) and a
control group receiving vehicle (50% water, 41% propylene
glycol, and 9% ethanol) (n Z 3). The treatment groups
consisted of a group receiving phenytoin (NDC 0641-0493,
30 mg/kg; Henry Schein Corporation) (nZ 10) and a group
receiving phenytoin plus lovastatin (0.65 mg/kg) (n Z 7).
Phenytoin was supplied from the vendor as pharmaceutical-
grade phenytoin sodium in liquid form with a concentration
of 50 mg/mL in 50% water, 41% propylene glycol, and 9%
ethanol. Lovastatin was supplied as the lovastatin sodium
salt and was dissolved directly in either 4.2 mL of phenytoin
sodium solution or 4.2 mL of the vehicle (50% water, 41%
propylene glycol, and 9% ethanol) to give a concentration of
1.13 mg/mL of lovastatin. Phenytoin, control vehicle, or
physiologic saline were delivered with miniosmotic pumps
(ALZET Osmotic Pumps, 2002, Cupertino, CA) at a 0.5-
mL/h delivery rate for a period of 2 weeks. Pumps were
replaced every 2 weeks as needed for the duration of the
experiment. Lovastatin, when present, was dissolved in the
same vehicle as phenytoin and when administered together
with phenytoin was dissolved in the same solution and
applied simultaneously in a single osmotic minipump.
Although a detailed time course for gingival overgrowth
development was not performed, a pilot study indicated that
only minimal levels of gingival overgrowth could be
observed at an experimental period of 6 weeks. Therefore,
the duration of the experimental period reported here was 12
weeks. The dose of lovastatin of 0.65 mg/kg is equivalent to1589
Assaggaf et alan intermediate human dose, which ranges from 0.3 to 1.2
mg/kg.8
Mouse Operations
Mice were preinjected with buprenorphine for analgesia 30
minutes before surgery. Then, mice were placed in an in-
duction chamber to induce anesthesia with isoﬂurane. Fur
was shaved from the mouse posterior to the shoulder, and
skin was wiped with povidone-iodine and 70% ethanol.
Using a scalpel blade 11, a small incision was made, and
then blunt dissection was performed with a hemostat. A
pump that contained physiological saline, vehicle, lova-
statin, phenytoin, or phenytoin plus lovastatin was placed
subcutaneously. Then, the wound was closed with autoclips
(427631; Clay Adams, New York, NY). All pumps were
primed in sterile physiological saline overnight at 37C to
ensure immediate release of the drugs on implantation.
Pumps were replaced every 2 weeks throughout the 12-
week experimental period. Mice were then euthanized and
heads were immediately placed in freshly made 4% para-
formaldehyde for 24 hours for ﬁxation.
Mouse Tissue Processing
After ﬁxation, mouse heads were washed under running tap
water to remove excess ﬁxative for 3 minutes. Then, each
head was immersed in 50 mL 0.5 mol/L EDTA at pH 8.0 for
decalciﬁcation. The EDTAwas changed every other day, and
the heads were incubated with EDTA at 4C on a shaker for a
6- to 8-week period. Serial X-rays assessed the degree of
decalciﬁcation. Anterior maxillae and mandibles were sepa-
rated from posterior dentition. Samples were trimmed so that
each sample included either maxillary central incisors or
maxillary molars or mandibular incisors or mandibular mo-
lars, with their respective surrounding gingival tissues.
Gross Morphology
Gross morphology images were taken with a stereomicroscope
(Carl Zeiss AG, Jena, Germany). To compare the gross
morphological differences among control and treatment groups,
papillary height and papillary area were analyzed on labial and
buccal gingival tissue of anterior and posterior upper and lower
jaws. All measurements were performed using the Olympus
Microsuite Five software version 5 (Richmond Hill, ON,
Canada). Means of these measurements were calculated and
subjected to one-way analysis of variance statistical analysis
with the Bonferroni post hoc test.
For embedding, samples were dehydrated in serial
ethanol concentrations: 50%, 70%, 95%, and 100% for half
a day, overnight, half a day, and overnight, respectively.
Samples were then placed in 100% acetone followed by
100% chloroform at 60C for 45 minutes each. Samples
were placed in parafﬁn for 3 successive hourly changes.
Samples were then embedded in parafﬁn using metal molds,1590cooled down at room temperature, and kept at 4C over-
night. The orientation of the samples during embedding was
set up for sagittal sectioning (Figure 1A), whereas posterior
tissues were for transverse sectioning. Sectioning was per-
formed using a microtome with stainless steel blades (Fisher
Scientiﬁc) producing 5-mm- thick sections. Slides were
baked at 60C for 2 hours to adhere sections to slides. For
each sample, each ﬁfth slide (three sections per slide) was
stained with hematoxylin-eosin to determine the range of
the ﬁne sections that were used for histomorphometric and
immunohistochemistry (IHC) analyses.
Histomorphometry
Slides were selected that contained buccal and lingual
gingival tissue and the decalciﬁed tooth structure that pro-
vided a landmark for orientation. Two different parameters
were measured in three representative central sections from
mandibles (lower jaw) and maxillae (upper jaw) from both
the anterior and posterior teeth to perform a comparative
histomorphometric analysis. The variables were the width of
the epithelium and the area of the epithelium.
For measuring the width of the epithelium, at least 10
arbitrary distances were measured from the outer layer of
the epithelium to the basement membrane in buccal and
lingual gingival tissue, separately. Then, the means of these
measurements were calculated, and one-way analysis of
variance with the Bonferroni post hoc test statistical analysis
was performed. For measuring the area of the epithelium,
two area measurements for each of the buccal and lingual
sides from each representative section were obtained, and
the means were calculated followed by one-way analysis of
variance with the Bonferroni post hoc statistical analyses.
All measurements were performed using the Olympus
Microsuite software. Signiﬁcance was declared at P < 0.05.
Immunohistochemistry
The expression levels of different epithelial to mesenchymal
transition (EMT) and ﬁbrosis markers were assessed by IHC.
Four sections per sample per marker were assayed. The IHC
technique used heat-based antigen retrieval followed by
immunoperoxidase staining. Sections were deparaﬁnized in
xylene for 10 minutes, followed by rehydration in serial con-
centrations of ethanol down to 75% and distilled water. Then,
sections were subjected to high-temperature antigen retrieval in
10 mmol/L citric acid at pH 6.0. Endogenous peroxidase was
inactivated with 3% hydrogen peroxide in methanol for 30
minutes. Endogenous immunoglobulin blocking was per-
formed using 10% normal serum in phosphate-buffered saline
from the same species in which the secondary antibody was
raised for 30 minutes. Endogenous avidin and biotin were
blocked for 20 minutes each to eliminate nonspeciﬁc binding
and background. Rabbit polyclonal primary antibodies were
used for detection of TGF-b1, CCN2, and LOXL2. A mouse
monoclonal primary antibody was used for detection ofajp.amjpathol.org - The American Journal of Pathology
Figure 1 A: Representation of orientation for embedding and
sectioning procedures of maxillary anterior tissues. B: Representative
images of gross morphology. C and D: Quantitation of papillary height and
papillary area of all samples obtained. These results were drawn from a
sample size of seven control, seven phenytoin-treated, and seven
phenytoin plus lovastatinetreated mice. Data are expressed as
means  SEM. *P < 0.05, Bonferroni post hoc tests.
Statins and Phenytoin Gingival OvergrowthE-cadherin. Sections stainedwith nonimmune rabbit andmouse
IgG primary antibody were used as the negative control. Sec-
tions were incubated with primary antibody diluted in 5%
normal serum in phosphate-buffered saline overnight at 4C.
Bound primary antibody was detected using Vectastain Elite
kits (Vector Laboratories) with biotinylated secondary antibody
for 30 minutes and immunoperoxidase staining as described by
the manufacturer. For IHC analysis of LOXL2 expression in
human tissues, frozen sections were ﬁxed in 100% acetone for
10 minutes at 37C and stained as previously described.9
Antibody Speciﬁcity
Antibody speciﬁcity for CCN2 was established by Western
blotting of nontreatedandTGF-b1etreated gingivalﬁbroblasts;
for TGF-b1, this was established by probing mouse gingival
tissue sections with antieTGF-b1 alone or with antieTGF-b
preabsorbedwith blocking peptide; for E-cadherin, byWestern
blotting of cultured gingival epithelial cells; and for LOXL2,
by shRNA knockdown of LOXL2 and Western blotting
of extracts of control and Ccn2 knockdown gingival ﬁbro-
blasts (Supplemental Figure S1).
Analysis of IHC
Threshold analysis was used to quantify the percentage of
stained area in two representative sections from each sampleThe American Journal of Pathology - ajp.amjpathol.orgusing ImageJ version 1.46 (NIH, Bethesda, MD). In this
technique, the threshold of a digital image is composed of
three different variables: hue, saturation, and brightness. By
setting the hue and saturation to maximum and adjusting the
brightness, the total area of tissue was determined. Next, by
adjusting the hue and brightness again, the area of stained
tissue in the section was determined.10 Then, the percentage
of the stained area normalized to the total tissue area in each
section was calculated. One-way analysis of variance sta-
tistical analyses with Bonferroni post hoc tests were ﬁnally
performed.
Results
Gross Morphology
Gross gingival morphology differences between groups were
investigated, and gingival overgrowth was apparent in the
maxillary anterior gingival tissue of phenytoin-treated mice
compared with control and phenytoin plus lovastatinetreated
mice (Figure 1B). Quantitative analyses (Figure 1, C and D)
revealed a trend toward an increase of papillary height in the
phenytoin group compared with the control group (PZ 0.094)
and a signiﬁcant reduction of the papillary height in the
phenytoin plus lovastatin groupwhen comparedwith phenytoin
(P Z 0.046). Area measurements revealed a signiﬁcant in-
crease in the phenytoin group when compared with the control
group (PZ 0.028). A comparison between the area measure-
ments of the phenytoin group and the phenytoin plus lovastatin
group revealed a trend toward reduction in the papillary area of
the phenytoin plus lovastatin group (PZ 0.094). No gingival
overgrowth could be identiﬁed around the anterior mandibles or
in the posterior mandible or maxillary molar areas (data not
shown). Thus, data suggest that phenytoin successfully induced
gingival overgrowth in anterior regions under these experi-
mental conditions. Lovastatin appears to prevent gingival
overgrowth development and is further analyzed below.
Histomorphometry of Tissue Sections
Quantitative histomorphometric analysis of tissue sections
from all mouse groups revealed increased epithelial thickness
and area in the maxillary anterior zone of phenytoin-treated
mice. In addition, lovastatin appeared to reduce the hyper-
plastic effect of phenytoin on gingival tissue as was observed
in the phenytoin plus lovastatinetreated mouse group
(Figure 2). The phenytoin-treated group had a 2.1-fold in-
crease in labial epithelial width and a 2.7-fold increase in
epithelial palatal width, implying an increased epithelial
volume. In addition, the phenytoin group had higher values
of epithelial area with a 1.9-fold labial increase and a 1.6-fold
increase in palatal area compared with the control group.
Interestingly, administration of both lovastatin and phenytoin
together prevented the hyperplastic effect of phenytoin and
resulted in the width and area of the epithelium essentially
equivalent to control levels (Figure 2A). By contrast,1591
Figure 2 Histomorphometric data of upper
anterior area. A: Representative sections of com-
parisons between sagittal sections of mouse maxil-
lary anterior areas obtained from three different
mouse groups (control, phenytoin, and phenytoin
plus lovastatin groups) stained with hematoxylin
and eosin (three sections per area per mouse). B:
Quantiﬁcation of maxillary anterior histomorpho-
metric data. These results were drawn from a sample
size of 9 control (black bars), 10 phenytoin-treated
(white bars), and 6 phenytoin plus lovastatine
treated (gray bars) mice. One-way analysis of vari-
ance analysis was signiﬁcant for labial epithelial
width (P < 0.00005), palatal epithelial width
(P< 0.00005), labial epithelial area (P< 0.05), and
palatal epithelial area (P< 0.02). Data are expressed
as means  SEM. *P < 0.05, ***P < 0.001, and
****P < 0.0001, Bonferroni post hoc tests. Scale
barZ 0.2 mm. CT, connective tissue; D, dentin; EP,
epithelium.
Assaggaf et almaxillary and mandibular posterior gingival epithelia had
either no differences or inconsistent results (data not shown).
Mice treated with lovastatin alone had no alteration in his-
tomorphometric parameters compared with saline or vehicle
controls (Supplemental Figure S2).
In summary, histomorphometric analysis revealed that
phenytoin increases the gingival epithelial volume in the
maxillary anterior zone and that lovastatin prevents devel-
opment of the hyperplastic effect of phenytoin. These
observations were greater on the palatal (lingual) side than
on the labial side of the gingival tissue.
Immunostaining for Markers of Fibrosis
Ccn2
Ccn2 was expressed mostly in the epithelium in all three
groups, with some connective tissue expression in the
phenytoin group, which was seen only in three phenytoin
samples. Qualitatively, the phenytoin group had increased
intensity of staining, suggesting overexpression of Ccn2 in
all areas of the epithelium when compared with the control
and the phenytoin plus lovastatin groups (Figure 3, A and
B). Quantitative analysis of Ccn2 staining was consistent
with these features except that the effect of lovastatin was
signiﬁcant for the palatal tissues and not for the labial1592tissues (Figure 3, C and D). Although Ccn2 was detected
in the connective tissue stroma, no obvious regulation by
phenytoin or lovastatin could be discerned under these
conditions. We conclude that phenytoin causes over-
expression of Ccn2 primarily in the epithelium of the
phenytoin-treated mice and that lovastatin largely pre-
vented the phenytoin-induced overexpression of Ccn2,
especially in palatal anterior gingiva.
TGF-b
TGF-b is a major inducer of CCN2. We therefore investi-
gated expression of TGF-b1 by IHC in these mouse tissues.
Data from mouse tissue sections assayed with antieTGF-b1
antibody revealed that phenytoin alone increased TGF-b
staining in both the gingival epithelium and connective
tissue in anterior gingival tissues when compared with the
control group (Figure 4, A and B). Interestingly, lovastatin
in the phenytoin plus lovastatin group prevented or dimin-
ished phenytoin-induced TGF-b1 expression in gingival
epithelium and connective tissues. The connective tissue
expression of TGF-b1 observed was both extracellular and
intracellular. The intensity of the staining was found to be
higher on the palatal side than the labial side of the gingival
tissue (Figure 4, A and B). Interestingly, connective tissue
staining for Tgf-b was similarly regulated in these tissues.ajp.amjpathol.org - The American Journal of Pathology
Statins and Phenytoin Gingival OvergrowthQuantitative analysis revealed that the phenytoin-treated
mice exhibited 3.7-fold higher TGF-b1 levels in the labial
gingiva and 2.3-fold higher levels in the palatal gingiva
compared with the control group (Figure 4, C and D). Mice
treated with phenytoin plus lovastatin had signiﬁcantly
reduced levels of TGF-b1 staining, even slightly lower than
levels seen in the control group, conﬁrming our qualitative
ﬁndings. Data indicate that TGF-b1 was overexpressed in the
phenytoin-treated mice in both the epithelium and connective
tissue. This overexpression was signiﬁcantly reduced in the
phenytoin plus lovastatin group.
E-Cadherin
Ccn2 and TGF-b are drivers of EMT in epithelial tissues.
Therefore, we next stained tissues for the classic epithelial cell
marker E-cadherin, which is down-regulated as cells undergo
EMT. E-cadherin staining revealed a lower intensity inThe American Journal of Pathology - ajp.amjpathol.orgphenytoin-treated mice compared with both control and
lovastatin-treated mice (Figure 5, A and B). Quantitative an-
alyses of areas stained suggest a partial restoration by lova-
statin of approximately 25% of E-cadherin staining on the
palatal side compared with phenytoin alone, whereas there
was no apparent effect of lovastatin on the labial side
(Figure 5, C and D). Besides intense epithelial staining, there
was some nonspeciﬁc immunoreactivity observed in the
connective tissue and periodontal ligament area in all groups,
including the nonimmune control. However, the nonimmune
control exhibited no epithelial staining, which supports that
epithelial E-cadherin staining is speciﬁc. Similar data were
obtained with a polyclonal E-cadherin antibody (data not
shown). It can be concluded that phenytoin strongly inhibits
E-cadherin staining in gingival epithelia, whereas lovastatin
has a limited ability to restore this expression on palatal
tissues.Figure 3 A and B: Ccn2 regulation by
phenytoin and phenytoin plus lovastatin in mouse
gingiva (labial view, A, and palatal view, B). C and
D: Quantiﬁcation of Ccn2 epithelial expression in
the mouse maxillary anterior area (labial tissue, C,
and palatal tissue, D). These results were drawn
from a sample size of eight control, eight
phenytoin-treated mice, and seven phenytoin plus
lovastatinetreated mice. One-way analysis of
variance analyses was not signiﬁcant for palatal
tissues. Data are expressed as means  SEM.
*P < 0.05, Bonferroni post hoc tests. Scale bars:
0.1 mm (A); 0.05 mm (B). Original magniﬁcation:
200 (A); 400 (B).
1593
Figure 4 A and B: Transforming growth factor
(TGF)-b regulation by phenytoin and phenytoin
plus lovastatin in mouse gingiva (labial view, A,
and palatal view, B). C and D: Quantiﬁcation of
TGF-b expression in the mouse maxillary anterior
area (labial tissue, C, and palatal tissue, D). Re-
sults were drawn from two sections per area per
mouse with a sample size of six control mice,
seven phenytoin-treated mice, and six phenytoin
plus lovastatinetreated mice. One-way analysis of
variance analyses were signiﬁcant for labial
(P < 0.00001) and palatal (P < 0.0005) epithelia.
Data are expressed as means  SEM. ***P < 0.001
and ****P < 0.0001, Bonferroni post hoc tests.
Scale bars: 0.1 mm (A); 0.05 mm (B). Original
magniﬁcation: 200 (A); 400 (B).
Assaggaf et alLOXL2
Evidence has been presented that LOXL2 is a driver of EMT in
the context of cancer.11,12 Additional ongoing studies suggest
that LOXL2 expression may contribute to human gingival
overgrowth (D. Saxena and P.C. Trackman, unpublished
data). We, therefore, wanted to determine whether Loxl2 was
expressed in the epithelium of phenytoin-treated mice and
whether lovastatin would modulate this expression. Staining
of mouse tissue sections with anti-LOXL2 antibody revealed
epithelial expression in all groups, and connective tissue
expression was seen only in one phenytoin sample on the
palatal side. The intensity of LOXL2 staining appeared to be
slightly higher in phenytoin-treated mice compared with the
control, whereas lovastatin appeared to lower the intensity of
LOXL2 expression below that of the control (Figure 6, A and
B). Quantitative analyses of stained areas indicate that the1594presence of lovastatin signiﬁcantly lowered LOXL2 expres-
sion in labial tissues, whereas a trend toward lowered
expression was observed in palatal tissues. Phenytoin alone
had no effect on the LOXL2 area stained. We conclude that
lovastatin appears to down-regulate LOXL2 expression in
gingival epithelia under these experimental conditions. It is
currently unclear whether phenytoin alone could have a
stimulatory effect on the intensity of LOXL2 epithelial
expression, which was not reﬂected in changes in the per-
centage of tissue area stained in this semiquantitative model.
LOXL2 in Human Gingival Overgrowth
LOXL2 levels in human phenytoin-induced gingival over-
growth tissues have not been previously measured, whereas
all other markers studied here have been previously measuredajp.amjpathol.org - The American Journal of Pathology
Figure 5 A and B: E-cadherin regulation by
phenytoin and phenytoin plus lovastatin in mouse
gingiva (labial view, A, and palatal view, B). C and
D: Quantiﬁcation of E-cadherin expression in the
mouse maxillary anterior area (labial tissue, C, and
palatal tissue, D). Results were drawn from two
sections per area per mouse with a sample size of
ﬁve control, six phenytoin-treated, and four
phenytoin plus lovastatinetreated mice. One-way
analysis of variance analyses were signiﬁcant for
labial epithelia (P < 0.05) and palatal epithelia
(P < 0.0005). Data are expressed as means  SEM.
*P < 0.05, **P < 0.01, and ****P < 0.0001,
Bonferroni post hoc tests. Scale bars: 0.1 mm (A);
0.02 mm (B). Original magniﬁcation: 200 (A);
1000 (B).
Statins and Phenytoin Gingival Overgrowthin the human gingival overgrowth tissues.5 We, therefore,
investigated the expression of LOXL2 in frozen gingival
tissue sections from human subjects taking phenytoin (nZ 4)
and control (nZ 4). Results indicate that LOXL2 is expressed
in the epithelium and connective tissue of both groups.
Interestingly, the phenytoin group had higher expression of
LOXL2 in both the epithelium and the connective tissue
compared with control tissues (Figure 7A). Quantitative an-
alyses indicate that the phenytoin group had the highest value
of epithelial area staining with a 3.05-fold increase when
compared with the controls (PZ 0.0007) (Figure 7B).
Discussion
Three types of drugs are known to induce gingival overgrowth
with variable degrees of ﬁbrosis and inﬂammation.13 TheseThe American Journal of Pathology - ajp.amjpathol.orgdrugs are the anticonvulsant phenytoin the immunosuppressant
ciclosporin, and the calcium channel blocker nifedipine.1e3 All
types of drug-induced gingival overgrowth had enlarged
gingival epithelial and connective tissues with variable degrees
of ﬁbrosis and inﬂammation in expanded connective tissue.14
Phenytoin-induced gingival overgrowth is clearly the most
ﬁbrotic form of drug-induced gingival overgrowth with high
expression of CCN2 and the lowest level of inﬂammatory cells.
Ciclosporin-induced gingival overgrowth is the least ﬁbrotic
form and contains more inﬂammatory cells and the lowest
CCN2 expression. Nifedipine-induced gingival overgrowth has
an intermediate degree of ﬁbrosis, CCN2 expression, and
inﬂammatory cell concentration when compared with
phenytoin- and cyclosporin-induced overgrowth.6 Oral hygiene
and genetic susceptibility and dose of drugs can partially
modulate the degree of gingival overgrowth.14e161595
Figure 6 A and B: LOXL2 regulation by
phenytoin and phenytoin plus lovastatin in mouse
gingiva (labial view, A, and palatal view, B). C and
D: Quantiﬁcation of LOXL2 expression by percent-
age of area stained in the mouse maxillary anterior
area (labial tissue, C, and palatal tissue, D). Data
are expressed as means  SEM. These results were
drawn from a sample size of six control, eight
phenytoin-treated mice, and six phenytoin plus
lovastatinetreated mice. One-way analysis of
variance analyses were nonsigniﬁcant in labial and
palatal tissues. Bonferroni post hoc tests were
nonsigniﬁcant for differences between control and
phenytoin groups, and differences between the
phenytoin and phenytoin plus lovastatin groups
were also nonsigniﬁcant. *P < 0.05, Bonferroni
post hoc tests. Scale bars: 0.1 mm (A); 0.05 mm
(B). Original magniﬁcation: 200 (A); 400 (B).
Assaggaf et alSeveral studies have been conducted to investigate drug-
induced gingival overgrowth pathogenesis. Inconsistent with
the clinical ﬁndings, some of these studies suggested that the
drugs causing gingival overgrowth directly inhibit ﬁbroblast
proliferation and/or extracellular matrix production by these
cells.17,18 More consistent with the in vivo ﬁndings, inﬂamma-
tory cytokine imbalance and up-regulation of proliferative
macrophages that secrete platelet-derived growth factor-bwere
found to mediate drug-induced gingival overgrowth. Evidence
for contributions of EMT in the development of gingival
overgrowth in vitro and in vivo has also been reported.5,19
It is important to discover new treatment modalities that
will permanently resolve gingival overgrowth lesions or pre-
vent their formation. We called attention to targeting ﬁbrotic
signaling pathways based on the mechanistic understanding
that lovastatin inhibits TGF-beinduced CCN2 expression
through indirect inhibition of CDC42 and RAC1 GTPases,1596which mediate TGF-beinduced CCN2 expression in human
gingival ﬁbroblasts.4 The further evaluation of the mecha-
nisms that lead to drug-induced gingival overgrowth and of
consequent therapeutic approaches requires the use of in vivo
animal models. Establishment of such models will provide
tools to monitor the temporal cellular and molecular associ-
ations of gingival overgrowth in vivo. Moreover, these models
will permit evaluation of novel therapeutic approaches. Pre-
vious studies have reported development of animal models
for drug-induced gingival overgrowth, but few have used
them to investigate therapeutic approaches. Models have been
established in dogs,20,21 monkeys,22 cats,23 rats,24e27 and
mice.28e30 The routes of drug administration in these studies
varied among daily intraperitoneal injections,29,30
gavage,24,26 or oral administration in diets.27,29 Although
these studies were successful in developing drug-induced
gingival overgrowth, the drug administration systems wereajp.amjpathol.org - The American Journal of Pathology
Figure 7 LOXL2 is up-regulated in human gingival overgrowth tissues.
A: Representative human gingival tissue sections stained with anti LOXL2
antibody. B: Quantiﬁcation of LOXL2 epithelial expression in human sam-
ples. These results were drawn from a sample size of four control and four
phenytoin-treated human subjects. Student’s t-test result was statistically
signiﬁcant for the difference in LOXL2 expression levels between the con-
trol and phenytoin groups. Data are expressed as means  SEM. n Z 4.
*P < 0.05. Scale bar Z 0.1 mm (A).
Statins and Phenytoin Gingival Overgrowthsuboptimal regarding the efﬁcacy and consistency of drug
administration.
The goals of our study included the induction of gingival
overgrowth in a mouse model by continuous and accurate
delivery of phenytoin and to test the effects of lovastatin
in the same model, also continuously and accurately
administered. We chose the BALB/cByJ mouse strain to
reduce genetic variability compared with outbred strains.
Moreover, a study by Meller et al30 presented BALB/c
mouse as a good model for cyclosporin-induced gingival
overgrowth.
Gross morphology data revealed signiﬁcant gingival
overgrowth in the phenytoin group when compared with the
control and the phenytoin plus lovastatin groups. These ef-
fects were observed only in the maxillary anterior gingival
area, whereas other areas had less consistent results. Clinical
studies of phenytoin-induced gingival overgrowth in
humans identiﬁed anterior maxillary and mandibular areas
as the most affected sites by phenytoin.31,32 The histo-
morphometric evaluation of mouse tissue sections conﬁrmed
gross morphology results. The phenytoin group exhibitedThe American Journal of Pathology - ajp.amjpathol.orgoverall increases in the volume of the gingival epithelial tissue
when compared with the control group. Interestingly, lova-
statin was capable of inhibiting the hyperplastic effect of
phenytoin. These ﬁndings were limited to the maxillary
anterior area, which is most severely affected in humans as
well. Additional studies of time and dose dependency coupled
with both RNA and protein expression studies will provide
additional information and potentially novel insights into the
molecular events that drive gingival overgrowth development.
EMT has been implicated in phenytoin-induced gingival
overgrowth development,5,19 and high epithelial expression
of mesenchymal proteins in phenytoin-induced overgrowth
observed here is of considerable interest. Several markers
of EMT were studied, including TGF-b1, E-cadherin,
Ccn2, and Loxl2. Limited by the semiquantitative measures
of protein expression and a single drug dose and a single
experimental time point used in this study, all markers
studied appeared to change either as a function of both
phenytoin and lovastatin treatments, with the possible
exception of LOXL2, which appears to have been modu-
lated only as a function of lovastatin. The fact that these
expressions were most obvious in the epithelium of mouse
gingival tissues supports the notion that EMT is occurring.
These data may further suggest that gingival overgrowth is
dependent on early changes in the epithelium in response to
systemic drug treatments. This ﬁnding seems to be unex-
pected in light of the fact that distribution of systemic drugs
depends on the systemic vasculature with initial drug
exposure occurring in the connective tissue rather than in
the avascular epithelium.
TGF-b1 is a strong inducer of EMT.5,33,34 Studies have
found high expression of TGF-b1 in phenytoin-induced
human samples.6,9 Our results in mice revealed substan-
tially higher expression of TGF-b1 in the phenytoin-treated
mouse group when compared with the control group in both
the epithelium and connective tissue, which were attenuated
in the presence of lovastatin. Consistent with our results,
HMG-CoA reductase inhibitors (statins) were found to
inhibit TGF-b1 expression in kidney and tooth extraction
sockets.35,36
Down-regulation of E-cadherin occurs in EMT and ﬁbrosis
in nonoral tissues.37,38 Our results indicate that phenytoin-
treated mice have lower expression of E-cadherin and that
lovastatin treatment resulted in partial attenuation of phenytoin
down-regulation of E-cadherin. The restoration of E-cadherin
expression by a RAS farnesylation inhibitor (FTI-277) in
human cancer cells39 and the ﬁnding that r GTPases promote
loss of E-cadherin and cancer metastasis40 are consistent with
our ﬁndings because lovastatin inhibits the formation of the
substrates needed for lipidation and activation of these
GTPases. The partial inhibition of the phenytoin-induced
E-cadherin down-regulation observed here could be due
to the presence of other potentially phenytoin-regulated
signaling pathways that repress E-cadherin, or alterna-
tively a higher dose of lovastatin may provide a better
outcome. The dose of lovastatin used was 0.65 mg/kg and1597
Assaggaf et alis based on an intermediate, but not maximum, human
dose. Human therapeutic doses of lovastatin range from
0.3 to 1.2 mg/kg.8,41
CCN2 levels have been positively correlated with ﬁbrosis
and EMT in phenytoin-induced gingival overgrowth and
other diseases5,6,42e44 and in the present study. Interestingly,
lovastatin in the phenytoin plus lovastatin group reduced the
phenytoin effect in inducing Ccn2 expression consistent
with in vitro studies.4 LOXL2 participates in EMT and
ﬁbrosis.45e47 For example, LOXL2 down-regulates E-cad-
herin levels resulting in b-catenin activation.47 Our analysis
of LOXL2 expression in human phenytoin-induced gingival
overgrowth samples revealed substantial overexpression of
LOXL2 in both the epithelium and the connective tissue.
Increased intensity of LOXL2 expression predominantly in
the epithelium was observed in the phenytoin-induced
gingival overgrowth mouse tissues, although measurements
of the percentage of the area stained did not reveal increased
staining. We suspect that the level of LOXL2 expression in
the epithelium was higher in phenytoin-treated mice, but
because of limitations to accurately quantitate the intensity of
staining, we can only suggest that LOXL2 expression was
increased based on qualitative observations (Figure 6). Data
suggest that the phenytoin plus lovastatin mouse group
contains lower levels of LOXL2 expression compared with
those observed in the other two groups. Because Loxl2 is
reported to regulate differentiation in multiple cell lineages,
such as epithelium47 and chondrocytes,48 our ﬁndings sug-
gest that lovastatin might modulate gingival epithelial
cell differentiation through down-regulation of LOXL2
expression. Any potential functional role of LOXL2 in
mediating phenytoin-induced gingival overgrowth clearly
requires additional study.
In summary, we report the development of a novel mouse
model for phenytoin-induced gingival overgrowth with
continuous and accurate drug delivery that replicates many of
themorphological andmolecular characteristics of phenytoin-
induced gingival overgrowth in humans.Moreover, we report
the use of this model to evaluate the effectiveness of a statin
drug, which, based on earlier in vitro studies, predicted that
lovastatin would be effective at attenuating phenytoin-
induced gingival overgrowth.3,4 Molecular proﬁles obtained
are consistent with EMT playing a role in the development of
gingival overgrowth, and expression of these markers and
tissue overgrowth appeared by the methods used to be either
attenuated or normalized by lovastatin. Evaluation of the
phenytoin-induced gingival overgrowth mouse model at both
the RNA and protein levels at earlier and later time points and
with different doses of drugsmay allowus to better understand
the temporal and spatial associations of themolecular markers
of EMT and ﬁbrosis. As noted, data so far point to the pos-
sibility that early signals in gingival overgrowth development
may emanate from the epithelium. Using the same drug
delivery system, mouse models for ciclosporin or nifedipine-
induced gingival overgrowth may, in addition, be highly
informative.1598Acknowledgments
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